search
Back to results

Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants

Primary Purpose

Infection, Viral, Enterovirus

Status
Withdrawn
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
400 U EV71 vaccine with adjuvant
Sponsored by
Sinovac Biotech Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Infection, Viral, Enterovirus

Eligibility Criteria

6 Months - 11 Months (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy males and females, aged from 6 to 11 months old Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
  2. Provided legal identification for the sake of recruitment.
  3. Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed consents.
  4. Birth weight more than 2500 grams

Exclusion Criteria:

  1. History of Hand-foot-mouth Disease
  2. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
  3. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  4. Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
  5. Epilepsy, seizures or convulsions history, or family history of mental illness
  6. Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
  7. History of asthma, angioedema, diabetes or malignancy
  8. History of thyroidectomy or thyroid disease that required medication within the past 12 months
  9. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  10. Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
  11. Acute illness or acute exacerbation of chronic disease within the past 7 days
  12. Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
  13. History of any blood products within 3 months
  14. Administration of any live attenuated vaccine within 28 days
  15. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
  16. Axillary temperature > 37.0 centigrade before vaccination
  17. Abnormal laboratory parameters before vaccination
  18. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Sites / Locations

  • GuangXi Center for Diseases Control and Prevention

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Group 1: 400U EV71 vaccine without adjuvant

Group 2: 400U EV71 vaccine without adjuvant

Group 3: 400U EV71 vaccine with adjuvant

Arm Description

60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart

60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant

60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant

Outcomes

Primary Outcome Measures

Neutralization antibody geometric mean titer in infants 28 days after immunization with 400U vaccine with or without aluminium hydroxide adjuvant
Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus >= 1:8

Secondary Outcome Measures

The rates and severity of solicited and unsolicited adverse events in infants following immunization as a Measure of Safety and Tolerability

Full Information

First Posted
March 13, 2013
Last Updated
July 26, 2021
Sponsor
Sinovac Biotech Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT01812135
Brief Title
Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants
Official Title
A Double-blind and Randomized, Phase II -02 Study With Inactivated EV71 Vaccines in Healthy Infants
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Withdrawn
Why Stopped
Based on the previous study results, inactivated EV71 vaccine with aluminum adjuvant was elected to be used for the efficacy Phase III study.
Study Start Date
September 2011 (undefined)
Primary Completion Date
November 2011 (Anticipated)
Study Completion Date
December 2011 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sinovac Biotech Co., Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A randomized, double-blind, phase II-02 clinical trial is to evaluate the safety and immunogenicity of an inactivated EV71 vaccine with or without aluminum adjuvant

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection, Viral, Enterovirus

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1: 400U EV71 vaccine without adjuvant
Arm Type
Experimental
Arm Description
60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart
Arm Title
Group 2: 400U EV71 vaccine without adjuvant
Arm Type
Experimental
Arm Description
60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant
Arm Title
Group 3: 400U EV71 vaccine with adjuvant
Arm Type
Experimental
Arm Description
60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant
Intervention Type
Biological
Intervention Name(s)
400 U EV71 vaccine with adjuvant
Other Intervention Name(s)
EV71 vaccine
Intervention Description
400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
Primary Outcome Measure Information:
Title
Neutralization antibody geometric mean titer in infants 28 days after immunization with 400U vaccine with or without aluminium hydroxide adjuvant
Description
Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus >= 1:8
Time Frame
2 months
Secondary Outcome Measure Information:
Title
The rates and severity of solicited and unsolicited adverse events in infants following immunization as a Measure of Safety and Tolerability
Time Frame
2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
11 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy males and females, aged from 6 to 11 months old Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator Provided legal identification for the sake of recruitment. Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed consents. Birth weight more than 2500 grams Exclusion Criteria: History of Hand-foot-mouth Disease Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain Congenital malformations or developmental disorders, genetic defects, or severe malnutrition Epilepsy, seizures or convulsions history, or family history of mental illness Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency History of asthma, angioedema, diabetes or malignancy History of thyroidectomy or thyroid disease that required medication within the past 12 months Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen Acute illness or acute exacerbation of chronic disease within the past 7 days Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis) History of any blood products within 3 months Administration of any live attenuated vaccine within 28 days Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days Axillary temperature > 37.0 centigrade before vaccination Abnormal laboratory parameters before vaccination Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yan-pin Li, MD
Organizational Affiliation
Guangxi Centers for Disease Control and Prevention
Official's Role
Principal Investigator
Facility Information:
Facility Name
GuangXi Center for Diseases Control and Prevention
City
Nanning
State/Province
Guangxi
Country
China

12. IPD Sharing Statement

Learn more about this trial

Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants

We'll reach out to this number within 24 hrs